Pear Therapeutics received market authorization from the FDA for its insomnia digital therapeutic, Somryst. It is Pear’s third product to receive FDA clearance, and the first product to be reviewed under the FDA’s new software precertification pilot program.

LEAVE A REPLY

Please enter your comment!
Please enter your name here